A5049856708- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders Research
- Gastrointestinal disorders and treatments
- Helicobacter pylori-related gastroenterology studies
- Celiac Disease Research and Management
- Immunodeficiency and Autoimmune Disorders
- Adolescent and Pediatric Healthcare
- Autoimmune and Inflammatory Disorders
- Pregnancy and Medication Impact
- Pharmaceutical studies and practices
- Pancreatitis Pathology and Treatment
- Probiotics and Fermented Foods
- Congenital gastrointestinal and neural anomalies
- Liver Diseases and Immunity
- Gut microbiota and health
- Clinical Nutrition and Gastroenterology
- Intestinal Malrotation and Obstruction Disorders
- Acute Lymphoblastic Leukemia research
- Diverticular Disease and Complications
- Digestive system and related health
- Hematological disorders and diagnostics
- Colorectal and Anal Carcinomas
- Child Nutrition and Water Access
Emek Medical Center
2016-2025
Technion – Israel Institute of Technology
2022-2025
SickKids Foundation
2020-2023
University of Toronto
2020-2023
Tel Aviv University
2019-2022
Tel Aviv Sourasky Medical Center
2022
Schneider Children's Medical Center
2014-2021
Hospital for Sick Children
2018-2021
Janssen (Switzerland)
2021
Merck (Germany)
2021
There are scarce data available on upadacitinib in children with Crohn's disease (CD). To evaluate the effectiveness and safety of as an induction therapy paediatric CD. This was a multicentre retrospective study between 2022 2024 treated for remission active CD conducted 30 centres worldwide affiliated IBD Interest Porto group ESPGHAN. We recorded demographic, clinical laboratory adverse events (AEs) at week 8 post-induction. The analysis primary outcome based upon intention-to-treat (ITT)...
Inflammatory bowel disease (IBD) and functional abdominal pain (FAP) are associated with debilitating symptoms frequent medical visits that may disrupt school functioning. The aim of this study was to assess school-related quality life absenteeism in children IBD, compared FAP healthy controls.School participation after-school activities data were obtained for 43 Crohn (CD), 31 ulcerative colitis (UC), 42 FAP, 30 age-matched controls the 2013-2014 year. We used a semistructured questionnaire...
Current data on ustekinumab therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBDU) are limited. We aimed to evaluate the effectiveness and safety of pediatric UC IBDU.
Abstract Background Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of as an induction pediatric UC IBD-U. Methods In this multicenter retrospective study, treated for remission active IBD-U from 30 centers worldwide were enrolled. Demographic, clinical laboratory data well adverse events (AEs) recorded at week 8 post induction. Results One hundred included...
Abstract Background Data regarding burden of depression and anxiety in pediatric-onset inflammatory bowel diseases (PIBD) are limited. We aimed to study the prevalence a nationwide cohort PIBD Methods were retrieved from epi-IIRN, 4 Israeli Health Maintenance Organizations covering 98% population 2005. matched children non-IBD controls for calculating time depression/anxiety. Patients with depression/anxiety prior IBD diagnosis excluded. Poor disease course (PDC) was defined as IBD-related...
Abstract Background Data on upadacitinib therapy in children with Crohn’s disease (CD) are scarce. We aimed to evaluate the effectiveness and safety of as an induction pediatric CD. Methods A multicenter retrospective study treated for remission active CD from 30 centers worldwide affiliated IBD Interest Porto group ESPGHAN between 2022 2024. Demographic, clinical, laboratory, imaging data well adverse events (AEs) were recorded at week 8 post induction. The analysis primary outcome was...
Background and Objectives: Data regarding long-term outcomes of gastrostomy-fed children is scarce. The aim the study was to analyze follow-up receiving percutaneous endoscopic gastrostomy (PEG) in terms nutritional outcomes, hospitalization, fundoplication rates. Materials Methods: medical records who underwent PEG placement between January 2002 June 2022 subsequently attended primary care clinics Clalit Health Services (CHS) Northeastern Israel, were reviewed this retrospective cohort...
Dose de-escalation of biologic therapies such as adalimumab (ADA) has the potential to reduce healthcare costs and mitigate adverse events. However, evidence supporting this approach in pediatric populations is limited, with existing studies primarily focused on adult cohorts. This study aimed evaluate safety efficacy ADA dose children diagnosed Crohn's disease (CD). We conducted a retrospective cohort involving CD patients from two inflammatory bowel units Israel. All were stable...
Data describing the incidence and risk factors for colectomy in pediatric ulcerative colitis (UC) is inconsistent. Our aim was to describe rate identify associated with a large cohort of children UC long-term follow-up.We performed retrospective chart review cases that were diagnosed at Schneider Children's Medical Center Israel between 1981 2013. Potential predictors including age diagnosis, sex, disease extent, severity indices, different therapeutic regimens during course assessed.Of 188...
Abstract Background The PAILOT trial was a randomized controlled aimed to evaluate proactive vs reactive therapeutic drug monitoring in children with Crohn’s disease (CD) treated adalimumab. Our aim this post hoc analysis of the assess efficacy and safety adalimumab combination treatment comparison monotherapy at week 72 after induction. Methods Participants were 6–17 years old, biologic naïve, moderate severe CD, who responded induction 4. Patients receiving immunomodulators baseline...
Objectives: Escalation of the ustekinumab (UST) maintenance dosage was effective in adults with Crohn disease (CD), but no data are available for children. We evaluated effectiveness and safety dose escalation UST pediatric CD. Methods: This a retrospective multicenter study from 25 centers affiliated IBD Interest Porto groups ESPGHAN. included children CD who initiated at standard dosing underwent either to intervals shorter than 8 weeks or re-induction due active disease. Demographic,...
Children with inflammatory bowel diseases (IBDs) are at risk of developing nutrition deficiencies, particularly because reduced intake, restrictive diets, malabsorption, and excessive nutrient loss. In this study, we aimed to assess the status trace elements, minerals, vitamins in a large cohort children IBDs.Medical records diagnosed IBDs during 2000-2016 were reviewed retrospectively. Retrieved data included demographics, disease characteristics, activity indices, anthropometric measures,...
Crohn disease (CD) is a chronic inflammatory bowel that, in the pediatric age group, tends to present with more severe form than adults and frequently takes complicated course (1). Biological treatment therapeutic option patients CD who either do not respond immunomodulators or extensive penetrating disease. therapies may also be used reduce symptoms when are unsuitable ineffective promote growth stunted children (2). Anti–tumor necrosis factor-α (TNF-α) agents, infliximab adalimumab, only...
Data on the outcomes of children with perianal Crohn's disease are limited. We aimed to assess phenotypic features at diagnosis and long-term disease-specific this phenotype.The medical records 296 pediatric onset patients disease, diagnosed from 2001 2015, were reviewed retrospectively. Baseline characteristics included age, sex, severity indices, laboratory data, endoscopic findings, anthropometric measurements. Main outcome measures time first flare, hospitalization, surgery, biological...
Data describing the incidence and risk factors for surgical interventions in pediatric Crohn's disease (CD) is inconsistent. Our aim was to describe rates of intestinal surgery identify associated a large cohort children with CD.Medical charts 482 CD from Schneider Pediatric Inflammatory Bowel Disease who were diagnosed between 1981 2013 carefully reviewed retrospectively.Of patients, 143 (29.7%) underwent median follow-up time 8.6 years (range, 1-30.5). Kaplan-Meier survival estimates...
The Paris modification of the Montreal classification for children with inflammatory bowel disease was accepted in 2011. We aimed to investigate long-term clinical outcomes patients diagnosed IBD during childhood a population-based cohort according at diagnosis.The medical records paediatric patients, from 2000 2016, were reviewed retrospectively. Main outcome measures included time first flare, hospitalisation, surgery, and biologic therapy.In Crohn's [n = 301, median age 14.2 years],...
The pediatric inflammatory bowel disease (PIBD) classes algorithm was developed to bring consistency labelling of colonic IBD, but labels are exclusively based on features atypical for ulcerative colitis (UC).The aim the study develop an and identify that discriminate between UC Crohn (CD).Baseline clinical, endoscopic, radiologic, histologic data, including PIBD class in 74 IBD (56: UC, 18: CD) patients were collected. additional common used perform initial clustering, using similarity...
Abstract Background and Aims Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness safety of as an induction pediatric UC IBD-U. Methods In this multicenter retrospective study, treated for remission active IBD-U from 30 centers worldwide were enrolled. Demographic, clinical laboratory data well adverse events (AEs) recorded at week 8 post induction. Results One hundred...
Objectives: A definitive diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) in patients who were initially diagnosed as inflammatory bowel disease-unclassified (IBDU) remains challenging. Our aims to describe the natural history pediatric-onset IBDU during prolonged period follow up and identify associated predictors for CD reclassification among them.Materials methods: In this retrospective single center study, out 723 with pediatric onset IBD, we identified 53 (7.3%) at Schneider...